Molecular and Genetic Analysis of Influenza A Viruses with Different Sensitivity to Rimantadine, Based on the M2 Protein Gene Sequence

Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(4):369-374

​ Rotanov M., Grebennikova T.V., Burtseva E.I., Shevchenko E.S.
influenza A virus rimantadine mutations
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(4):369-374

Abstract

The paper presents the results of molecular analysis of epidemic strains of influenza A in different years and within subtypes H1 and H3, manifesting different sensitivity to rimantadine. Analysis was performed on the influenza A virus M2 protein gene sequence. In order to detect mutations in the viral genome, analysis was performed on 15 strains of subtype A(H3N2) and 16 strains of subtype A(H1N1), isolated at the Russian Federation in 1995–2007. Analysis of registered nucleotide sequences of the M2 protein enabled to identify mutations confering resistance to rimantadine. Apart from known mutations, additional mutations were detected for each subtype which may be considered as new markers for the identification of rimantadine-resistant strains.

  • 1. Грипп. Руководство для врачей. Под ред. Карпухи­на Г. И. СПб.: Гиппократ; 2001. - 360 с.
  • 2. World Health Organization. Fact sheet №211; March 2003; Available from http://www.who.int/mediacentre/ factsheets/fs211/en
  • 3. Информационное письмо Минздравсоцразвития России от 13.06.2007. № 0100/6026-07-32 «Об итогах эпидсезона по гриппу и ОРВИ в 2006-2007 гг. и прогнозе на сезон 2007-2008 гг.»
  • 4. Ленева И.А., Шустер А.М. Противовирусные химиопрепараты: эффективность против вирусов гриппа А подтипа H5N1. Вопросы вирусологии 2006; 5:4-7.
  • 5. World Health Organization. WHO consultation on priority public health interventions before and during an influenza pandemic. Working group three - Antiviralstheir use and availability; 2004 March 16-18; Geneva, Switzerland. Available from http://www.who.int/csr/disease/avian_influenza/final.pdf
  • 6. Глушков Р.Г., Фадеева Н.И., Ленева И.А. и др. Молекулярно-биологические особенности действия Арбидола - нового противовирусного препарата. Хим.- фарм. журн. 1992; 2:8-15.
  • 7. Ленева И.А., Глушков Р.Г., Гуськова Т.А. Лекарственные средства для химиотерапии и химиопрофилактики гриппа: особенности механизма действия, эффективность и безопасность (обзор). Хим.-фарм. журн. 2004; 11:8-14.
  • 8. CDC. Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory.MMWR 1997; 46:1-25. Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/00047346.htm
  • 9. Hayden F.G., Belshe R.B., Clover R.D., Hay A.J., Pyke S. Emergence and apparent transmission of rimantadineresistant influenza A virus in families. N Engl J Med 1989; 321:1696-702.
  • 10. Shiraishi K., K. Mitamura, Y. Sakai-Tagawa, Goto H., Sagaya N., Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188:57-61.
  • 11. Deyde V.M., Gubareva L.V., Xu X., Shaw M, Smith C., Klimov A.I.. Surveillance of resistance to adamantanes among influenza A (H3N2) and A(H1N1) viruses isolated worldwide (2005-2007). Options for the Control of Influenza VI Conference [Proceedings on CD ROM]; 2007 June 17-23; Toronto, Ontario, Canada; p. 230.
  • 12. Burtseva E., Shevchenko E., Zaplatnikov A., Merkulova L., Slepushkin A. Influenza viruses sensitivity to antivirals in Russia. Options for the Control of Influenza VI Conference [Proceedings on CD ROM]; 2007 June 17-23; Toronto, Ontario, Canada; p.231.
  • 13. Федякина И.Т., Ямникова С.С., Галегов Г.А., Львов Д. К. Действие противовирусных препаратов на репродукцию вируса гриппа птиц А/Н5, изолированного в России. Вопросы вирусологии 2005; (4):35-7.
  • 14. Шевченко Е.С., Бурцева Е.И., Слепушкин А.Н. Спектр чувствительности к римантадину вирусов гриппа А, циркулировавших в эпидемических сезонах 2002-2004 гг. Вопросы вирусологии 2005; (5):32-5.
  • 15. Belshe R.B., Smith M.N., Hall C.B., Betts R., Hay A.J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988; 62:1508-12.
  • 16. Hay A.Y., Wolstenholme J., Skehel J., Smith M.N. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4:3021-24.
  • 17. Lamb R.A., Zabedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected –cell surface. Cell. 1985; 40:627-33.
  • 18. Yi-Ying Cheng, Min-Shi Lee, Mei-Shang Ho. The Multicountry emergence of adamantane-resistant influenza A (H3) Viruses is due to a single lineage that possesses district internal genes. Options for the control of influenza. VI Conference [Proceedings on CD ROM]; 2007 June 17-23; Toronto, Ontario, Canada; p. 232.
  • 19. Monto A.S., McKimm-Breschkin J.L., Macken C., et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395- 402.
  • 20. World Health Organization. Fact sheet Avian Influenza. 2006 February; Available from http://www.who.int/mediacentre/factsheets/avian_influenza/en/.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared